NovaBay Pharma (NBY) Tops Q4 EPS by 18c

NovaBay Pharma (NYSE: NBY) reported Q4 EPS of $0.11, $0.18 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.23 million.

• Avenova sales of $3.9 million increased 146% year-over-year and 26% over 3Q16;
• Prescription sales into the pharmacy channel were $3.0 million, up 550% year-over-year and up 45% over 3Q16;
• New prescribers increased by over 1,000;
• Total number of medical professionals who have prescribed Avenova increased by 17% from the third quarter of 2016 to more than 8,700.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Stardust Power (SDST) Tops Q2 EPS by 1c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c